Page last updated: 2024-11-05

tranexamic acid and Thrombocytopenia

tranexamic acid has been researched along with Thrombocytopenia in 26 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Thrombocytopenia: A subnormal level of BLOOD PLATELETS.

Research Excerpts

ExcerptRelevanceReference
"This trial will assess the safety and efficacy of using prophylactic tranexamic acid during a period of intensive chemotherapy and associated thrombocytopenia in people with haematological disorders."9.30The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri ( Curnow, E; Dyer, C; Estcourt, LJ; McQuilten, Z; Powter, G; Stanworth, SJ; Wood, EM, 2019)
"A controlled, randomized, double-blind study was performed to assess the effect of the oral antifibrinolytic agent tranexamic acid in patients with amegakaryocytic thrombocytopenia as regards their need for platelet transfusions and the number of bleeding episodes experienced."9.07Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. ( Alling, D; Fricke, W; Griffith, P; Kimball, J; Klein, H, 1991)
"To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in people with haematological disorders."8.93Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. ( Brunskill, SJ; Desborough, M; Doree, C; Estcourt, LJ; Hopewell, S; Murphy, MF; Stanworth, SJ, 2016)
"To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in patients with haematological disorders."8.89Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. ( Brunskill, SJ; Doree, C; Estcourt, LJ; Murphy, MF; Stanworth, S; Trivella, M; Wardrop, D, 2013)
"The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopenia requiring supportive platelet transfusion following myeloablative therapy for hematologic disorders."8.31Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. ( Brown, SP; de Laat, B; El Kassar, N; Gernsheimer, TB; Herren, H; Holle, LA; Ilich, A; Key, NS; Lucas, AT; May, S; Triulzi, DJ; Wolberg, AS, 2023)
"This trial will assess the safety and efficacy of using prophylactic tranexamic acid during a period of intensive chemotherapy and associated thrombocytopenia in people with haematological disorders."5.30The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri ( Curnow, E; Dyer, C; Estcourt, LJ; McQuilten, Z; Powter, G; Stanworth, SJ; Wood, EM, 2019)
"Tranexamic acid was extremely well tolerated in this newborn."5.28Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants. ( Bernstein, M; Hanna, BD, 1989)
"A controlled, randomized, double-blind study was performed to assess the effect of the oral antifibrinolytic agent tranexamic acid in patients with amegakaryocytic thrombocytopenia as regards their need for platelet transfusions and the number of bleeding episodes experienced."5.07Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. ( Alling, D; Fricke, W; Griffith, P; Kimball, J; Klein, H, 1991)
"To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in people with haematological disorders."4.93Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. ( Brunskill, SJ; Desborough, M; Doree, C; Estcourt, LJ; Hopewell, S; Murphy, MF; Stanworth, SJ, 2016)
"To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in patients with haematological disorders."4.89Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. ( Brunskill, SJ; Doree, C; Estcourt, LJ; Murphy, MF; Stanworth, S; Trivella, M; Wardrop, D, 2013)
"The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopenia requiring supportive platelet transfusion following myeloablative therapy for hematologic disorders."4.31Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. ( Brown, SP; de Laat, B; El Kassar, N; Gernsheimer, TB; Herren, H; Holle, LA; Ilich, A; Key, NS; Lucas, AT; May, S; Triulzi, DJ; Wolberg, AS, 2023)
"Tranexamic acid has been advocated for patients with severe bleeding tendency due to thrombocytopenia not responding to platelet transfusions."3.69Microscopic haematuria as a relative contraindication for tranexamic acid. ( Schultz, M; van der Lelie, H, 1995)
"The most robust data for the treatment of menorrhagia are for tranexamic acid."2.47Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. ( Bates, JS; Buie, LW; Woodis, CB, 2011)
"Tranexamic acid was extremely well tolerated in this newborn."1.28Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants. ( Bernstein, M; Hanna, BD, 1989)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19904 (15.38)18.7374
1990's7 (26.92)18.2507
2000's2 (7.69)29.6817
2010's11 (42.31)24.3611
2020's2 (7.69)2.80

Authors

AuthorsStudies
Ilich, A1
Gernsheimer, TB1
Triulzi, DJ1
Herren, H1
Brown, SP1
Holle, LA1
Lucas, AT1
de Laat, B1
El Kassar, N1
Wolberg, AS1
May, S1
Key, NS1
Estcourt, LJ4
McQuilten, Z1
Powter, G1
Dyer, C1
Curnow, E1
Wood, EM1
Stanworth, SJ3
Wardrop, D1
Brunskill, SJ2
Doree, C3
Trivella, M2
Stanworth, S1
Murphy, MF2
Schlitter, MC1
Rühl, H1
Thiesler, T1
Penner, AH1
Berens, C1
Wolf, D1
Mayer, K1
Revollo, JY1
Cuffy, MC1
Witte, DP1
Paterno, F1
Alloway, RR1
Woodle, ES1
Desborough, M2
Hopewell, S2
Hadjinicolaou, AV1
Chaimani, A1
Vyas, P1
Tay, J1
Allan, D1
Beattie, S1
Bredeson, C1
Fergusson, D1
Maze, D1
Sabloff, M1
Thavorn, K1
Tinmouth, A1
Yadav, SP1
Sachdeva, A1
Bhat, S1
Katewa, S1
Kerros, H1
Roule, V1
Ivascau, C1
Labombarda, F1
Bates, JS1
Buie, LW1
Woodis, CB1
Weightman, WM1
Gibbs, NM1
Coppola, A1
Simone, CD1
Palmieri, NM1
Coppola, D1
Lanza, F1
Ruosi, C1
Amoriello, A1
Di Minno, G1
Mori, T1
Aisa, Y1
Shimizu, T1
Yamazaki, R1
Mihara, A1
Yajima, T1
Hibi, T1
Ikeda, Y1
Okamoto, S1
Astedt, B1
Henriksson, P1
Nilsson, IM1
Svanberg, L1
Schultz, M1
van der Lelie, H1
Fernández Lucas, M1
Liaño, F1
Navarro, JF1
Sastre, JL1
Quereda, C1
Ortuño, J1
O'Brien, JG2
Battistini, B2
Farmer, P2
Johnson, RJ2
Zaharia, F2
Plante, GE1
Sirois, P2
Katsaros, D1
Grundfest-Broniatowski, S1
Gortzak, RA1
Huijgens, PC1
Lindquist, O1
Bagge, L1
Saldeen, T1
Fricke, W1
Alling, D1
Kimball, J1
Griffith, P1
Klein, H1
Hanna, BD1
Bernstein, M1
Bell, AJ1
Chisholm, M1
Hickton, M1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-blind, Randomised Controlled Trial Evaluating the Safety and Efficacy of Antifibrinolytics (Tranexamic Acid) in Patients With Haematological Malignancies With Severe Thrombocytopenia[NCT03136445]Phase 3616 participants (Actual)Interventional2015-06-30Completed
Platelet Transfusion Requirements in Hematopoietic Transplantation(PATH Pilot)[NCT02650791]Phase 3100 participants (Actual)Interventional2016-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

5 reviews available for tranexamic acid and Thrombocytopenia

ArticleYear
Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders.
    The Cochrane database of systematic reviews, 2013, Jul-29, Issue:7

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Erythrocyte Transfusion; Hematologic Diseases; Hemorrhag

2013
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders.
    The Cochrane database of systematic reviews, 2016, Mar-15, Volume: 3

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Erythrocyte Transfusion; Hematologic Diseases; Hemorrhag

2016
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
    The Cochrane database of systematic reviews, 2016, Oct-31, Volume: 10

    Topics: Benzoates; Bone Marrow Diseases; Chronic Disease; Deamino Arginine Vasopressin; Hemorrhage; Hemostat

2016
Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy.
    Pharmacotherapy, 2011, Volume: 31, Issue:11

    Topics: Animals; Antifibrinolytic Agents; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Meno

2011
Management of coagulation: an Australian perspective.
    Current opinion in anaesthesiology, 2012, Volume: 25, Issue:1

    Topics: Australia; Blood Coagulation Disorders; Factor VIIa; Hemorrhage; Humans; Perioperative Care; Platele

2012

Trials

3 trials available for tranexamic acid and Thrombocytopenia

ArticleYear
The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri
    Trials, 2019, Oct-15, Volume: 20, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Australia; Double-Blind

2019
Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study.
    BMJ open, 2016, 10-24, Volume: 6, Issue:10

    Topics: Adolescent; Adult; Antifibrinolytic Agents; Blood Platelets; Female; Hematopoietic Stem Cell Transpl

2016
Lack of efficacy of tranexamic acid in thrombocytopenic bleeding.
    Transfusion, 1991, Volume: 31, Issue:4

    Topics: Anemia, Aplastic; Blood Transfusion; Hemorrhage; Humans; Myelodysplastic Syndromes; Platelet Transfu

1991

Other Studies

18 other studies available for tranexamic acid and Thrombocytopenia

ArticleYear
Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia.
    Blood advances, 2023, 03-28, Volume: 7, Issue:6

    Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrinolysin; Fibrinolysis; Hemorrhage; Humans

2023
Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
    Blood advances, 2023, Jul-11, Volume: 7, Issue:13

    Topics: Blood Coagulation Disorders; Humans; Thrombocytopenia; Tranexamic Acid

2023
Paraneoplastic disseminated intravascular coagulation caused by splenic littoral cell angioma.
    Annals of hematology, 2014, Volume: 93, Issue:10

    Topics: Blood Component Transfusion; Chest Pain; Combined Modality Therapy; Disseminated Intravascular Coagu

2014
Case Report: Hemolytic Anemia Following Deceased Donor Renal Transplantation Associated With Tranexamic Acid Administration for Disseminated Intravascular Coagulation.
    Transplantation proceedings, 2015, Volume: 47, Issue:7

    Topics: Aged; Anemia, Hemolytic; Antifibrinolytic Agents; Diabetes Mellitus, Type 2; Disseminated Intravascu

2015
Successful control of massive gastrointestinal bleeding following umbilical cord blood transplantation (UCBT) by use of recombinant activated factor VII (rFVIIa) and octreotide infusion.
    Pediatric hematology and oncology, 2010, Volume: 27, Issue:1

    Topics: beta-Thalassemia; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Delayed Graft F

2010
Management of May-Hegglin anomaly referred for coronary artery bypass.
    Platelets, 2011, Volume: 22, Issue:6

    Topics: Adult; Anesthetics; Blood Platelets; Cell Size; Coronary Artery Bypass; Diabetes Complications; Diab

2011
Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2007, Volume: 18, Issue:2

    Topics: Adolescent; Blood Loss, Surgical; Blood Platelet Disorders; Drug Administration Schedule; Factor VII

2007
Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation.
    American journal of hematology, 2007, Volume: 82, Issue:9

    Topics: Antifibrinolytic Agents; Bilirubin; Child; Female; Hematopoietic Stem Cell Transplantation; Hepatic

2007
Regression of hemangioma--thrombocytopenia syndrome.
    Acta obstetricia et gynecologica Scandinavica, 1982, Volume: 61, Issue:5

    Topics: Adolescent; Female; Hemangioma; Humans; Syndrome; Thrombocytopenia; Tranexamic Acid; Uterine Neoplas

1982
Microscopic haematuria as a relative contraindication for tranexamic acid.
    British journal of haematology, 1995, Volume: 89, Issue:3

    Topics: Adult; Contraindications; Female; Hematuria; Hemorrhagic Disorders; Humans; Male; Middle Aged; Throm

1995
Acute renal failure secondary to antifibrinolytic therapy.
    Nephron, 1995, Volume: 69, Issue:4

    Topics: Acute Kidney Injury; Aged; Humans; Male; Myelodysplastic Syndromes; Thrombocytopenia; Tranexamic Aci

1995
Aprotinin, an antifibrinolytic drug, attenuates bradykinin-induced permeability in conscious rats via platelets and neutrophils.
    Canadian journal of physiology and pharmacology, 1997, Volume: 75, Issue:6

    Topics: Animals; Antifibrinolytic Agents; Aprotinin; Blood Platelets; Bradykinin; Capillary Permeability; Ce

1997
Effects of tranexamic acid and aprotinin on PAF-induced vascular permeability in normal, thrombocytopenic or neutropenic rats.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 1997, Volume: 46 Suppl 2

    Topics: Animals; Antifibrinolytic Agents; Aprotinin; Bronchi; Capillary Permeability; Male; Neutropenia; Pla

1997
Successful management of visceral Klippel-Trenaunay-Weber syndrome with the antifibrinolytic agent tranexamic acid (cyclocapron): a case report.
    The American surgeon, 1998, Volume: 64, Issue:4

    Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Tests; Colon, Sigmoid; Disseminated Intravascular

1998
[A patient with thrombocytopenia: what do I do?].
    Nederlands tijdschrift voor tandheelkunde, 1999, Volume: 106, Issue:12

    Topics: Adult; Antifibrinolytic Agents; Humans; Male; Methylprednisolone; Oral Hemorrhage; Postoperative Car

1999
Induction of endogenous fibrinolysis inhibition in the dog. Effect of intravascular coagulation and release of free fatty acids.
    Acta chirurgica Scandinavica, 1976, Volume: 142, Issue:1

    Topics: Animals; Batroxobin; Blood Platelets; Dogs; Endotoxins; Fatty Acids, Nonesterified; Female; Fibrinol

1976
Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants.
    The American journal of pediatric hematology/oncology, 1989,Summer, Volume: 11, Issue:2

    Topics: Cyclohexanecarboxylic Acids; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Fema

1989
Reversal of coagulopathy in Kasabach-Merritt syndrome with tranexamic acid.
    Scandinavian journal of haematology, 1986, Volume: 37, Issue:3

    Topics: Afibrinogenemia; Blood Coagulation Disorders; Buttocks; Combined Modality Therapy; Cyclohexanecarbox

1986